T. Rowe Price Investment Management, Inc. Merus N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Merus N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 509,761 shares of MRUS stock, worth $27.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
509,761
Previous 808,576
36.96%
Holding current value
$27.1 Million
Previous $34 Million
36.9%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding MRUS
# of Institutions
195Shares Held
62.2MCall Options Held
355KPut Options Held
96.5K-
Wellington Management Group LLP Boston, MA4.72MShares$251 Million0.04% of portfolio
-
Commodore Capital LP New York, NY4.47MShares$238 Million18.43% of portfolio
-
Rtw Investments, LP New York, NY4.17MShares$221 Million2.88% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.37MShares$179 Million7.27% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.17MShares$169 Million3.38% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.44B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...